Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 23, 2026.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)

Paul Moayyedi, Christopher N Andrews, Glenda MacQueen and 9 more

Journal of the Canadian Association of Gastroenterology · 2019 · CC BY

doi:10.1093/jcag/gwy071

Abstract

Background & aims. Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders, affecting about 10% of the general population globally. The aim of this consensus was to develop guidelines for the management of IBS.

Methods. A systematic literature search identified studies on the management of IBS. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a multidisciplinary group of clinicians and a patient.

Results. Consensus was reached on 28 of 31 statements. Irritable bowel syndrome is diagnosed based on symptoms; serological testing is suggested to exclude celiac disease, but routine testing for C-reactive protein (CRP), fecal calprotectin or food allergies is not recommended. A trial of a low fermentable oligosaccharides, disaccharides, monosaccharides, polyols (FODMAP) diet is suggested, while a gluten-free diet is not. Psyllium, but not wheat bran, supplementation may help reduce symptoms. Alternative therapies such as peppermint oil and probiotics are suggested, while herbal therapies and acupuncture are not. Cognitive behavioural therapy and hypnotherapy are suggested psychological therapies. Among the suggested or recommended pharmacological therapies are antispasmodics, certain antidepressants, eluxadoline, lubiprostone, and linaclotide. Loperamide, cholestyramine and osmotic laxatives are not recommended for overall IBS symptoms. The nature of the IBS symptoms (diarrhea-predominant or constipation-predominant) should be considered in the choice of pharmacological treatments.

Conclusions. Patients with IBS may benefit from a multipronged, individualized approach to treatment, including dietary modifications, psychological and pharmacological therapies.

References 177

  1. 1.

    Lacy BE, Mearin F, Chang L, et al Bowel disorders. Gastroenterology2016;150:1393–407.e5.

    Not in our library10.1053/j.gastro.2016.02.031

  2. 2.

    Lovell RM, Ford AC Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol2012;10(7):712–721.e4.

    Not in our library10.1016/j.cgh.2012.02.029

  3. 3.

    Sperber AD, Dumitrascu D, Fukudo S, et al The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut2017;66(6):1075–82.

    Not in our library10.1136/gutjnl-2015-311240

  4. 4.

    Thompson WG, Irvine EJ, Pare P, et al Functional gastrointestinal disorders in Canada: First population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci2002;47(1):225–35.

    Not in our library10.1023/a:1013208713670

  5. 5.

    Palsson OS, van Tilburg MA, Simren M, et al Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) [Abstract Mo1642]. Gastroenterology2016;150:S739–40.

    Not in our library

  6. 6.

    Drossman DA Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology2016;150:1262–79.

    Not in our library10.1053/j.gastro.2016.02.032

  7. 7.

    Ford AC, Moayyedi P, Lacy BE, et al al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol2014;109(Suppl 1):S2–26; quiz S27.

    Not in our library10.1038/ajg.2014.187

  8. 8.

    Chang L, Lembo A, Sultan S American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology2014;147(5):1149–72.e2.

    Not in our library10.1053/j.gastro.2014.09.002

  9. 9.

    Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924–6.

    Not in our library10.1136/bmj.39489.470347.ad

  10. 10.

    Sultan S, Falck-Ytter Y, Inadomi JM The AGA institute process for developing clinical practice guidelines part one: Grading the evidence. Clin Gastroenterol Hepatol2013;11(4):329–32.

    Not in our library10.1016/j.cgh.2013.02.001

  11. 11.

    Bressler B, Marshall JK, Bernstein CN, et al; Toronto Ulcerative Colitis Consensus Group Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology2015;148(5):1035–1058.e3.

    Not in our library10.1053/j.gastro.2015.03.001

  12. 12.

    Enns RA, Hookey L, Armstrong D, et al Clinical practice guidelines for the use of video capsule endoscopy. Gastroenterology2017;152(3):497–514.

    Not in our library10.1053/j.gastro.2016.12.032

  13. 13.

    Nguyen GC, Seow CH, Maxwell C, et al; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology2016;150(3):734–757.e1.

    Not in our library10.1053/j.gastro.2015.12.003

  14. 14.

    Fallone CA, Chiba N, van Zanten SV, et al The Toronto consensus for the treatment of helicobacter pylori infection in adults. Gastroenterology2016;151(1):51–69.e14.

    Not in our library10.1053/j.gastro.2016.04.006

  15. 15.

    Nguyen GC, Bernstein CN, Bitton A, et al Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: CANADIAN Association of Gastroenterology. Gastroenterology2014;146(3):835–848.e6.

    Not in our library10.1053/j.gastro.2014.01.042

  16. 16.

    Liu L, Andrews C, Armstrong D, et al Clinical practice guidelines for the assessment of uninvestigated esophageal dysphagia. J Can Assoc Gastroenterol2018;1:5–19.

    Not in our library10.1093/jcag/gwx008

  17. 17.

    Guyatt GH, Oxman AD, Kunz R, et al; GRADE Working Group Going from evidence to recommendations. BMJ2008;336(7652):1049–51.

    Not in our library10.1136/bmj.39493.646875.ae

  18. 18.

    Ford AC, Chey WD, Talley NJ, et al Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: Systematic review and meta-analysis. Arch Intern Med2009;169(7):651–8.

    Not in our library10.1001/archinternmed.2009.22

  19. 19.

    Zipser RD, Patel S, Yahya KZ, et al Presentations of adult celiac disease in a nationwide patient support group. Dig Dis Sci2003;48(4):761–4.

    Not in our library10.1023/a:1022897028030

  20. 20.

    Menees SB, Powell C, Kurlander J, et al A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol2015;110(3):444–54.

    Not in our library10.1038/ajg.2015.6

  21. 21.

    Sood R, Camilleri M, Gracie DJ, et al Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. Am J Gastroenterol2016;111(10):1446–54.

    Not in our library10.1038/ajg.2016.308

  22. 22.

    Ford AC, Bercik P, Morgan DG, et al Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology2013;145(6):1262–70.e1.

    Not in our library10.1053/j.gastro.2013.08.048

  23. 23.

    Hilmi I, Hartono JL, Pailoor J, et al Low prevalence of ‘classical’ microscopic colitis but evidence of microscopic inflammation in Asian irritable bowel syndrome patients with diarrhoea. BMC Gastroenterol2013;13:80.

    Not in our library10.1186/1471-230x-13-80

  24. 24.

    Ishihara S, Yashima K, Kushiyama Y, et al Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: A prospective multi-center study utilizing colonoscopy. J Gastroenterol2012;47(10):1084–90.

    Not in our library10.1007/s00535-012-0573-4

  25. 25.

    Chey WD, Nojkov B, Rubenstein JH, et al The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: Results from a prospective, controlled US trial. Am J Gastroenterol2010;105(4):859–65.

    Not in our library10.1038/ajg.2010.55

  26. 26.

    Gu HX, Zhang YL, Zhi FC, et al Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case–control study. Int J Colorectal Dis2011;26(7):935–40.

    Not in our library10.1007/s00384-011-1163-2

  27. 27.

    Akhtar AJ, Shaheen MA, Zha J Organic colonic lesions in patients with irritable bowel syndrome (IBS). Med Sci Monit2006;12(9):CR363–7.

    Not in our library

  28. 28.

    Hamm LR, Sorrells SC, Harding JP, et al Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol1999;94(5):1279–82.

    Not in our library10.1111/j.1572-0241.1999.01077.x

  29. 29.

    El-Salhy M, Halwe J, Lomholt-Beck B, et al The prevalence of inflammatory bowel diseases, microscopic colitis, and colorectal cancer in patients with irritable bowel syndrome. Gastroenterol Insights2011;3:3.

    Not in our library

  30. 30.

    Şimşek Z, Tuncer NC, Alagüzlü H, et al Two gastrointestinal conditions with similar symptoms and endoscopic appearance: Irritable bowel syndrome and microscopic colitis. Turk J Med Sci2015;45(2):393–7.

    Not in our library10.3906/sag-1401-88

  31. 31.

    Ozdil K, Sahin A, Calhan T, et al The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome. BMC Gastroenterol2011;11:96.

    Not in our library10.1186/1471-230x-11-96

  32. 32.

    Carmona-Sánchez R, Carrera-Álvarez MA, Pérez-Aguilar RM [Prevalence of microscopic colitis in patients with irritable bowel syndrome with diarrhea predominance]. Rev Gastroenterol Mex2011;76(1):39–45.

    Not in our library

  33. 33.

    Tunçer C, Cindoruk M, Dursun A, et al Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome. Acta Gastroenterol Belg2003;66(2):133–6.

    Not in our library

  34. 34.

    De Silva AP, Nandasiri SD, Hewavisenthi J, et al Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol2012;47(6):619–24.

    Not in our library10.3109/00365521.2012.666672

  35. 35.

    Pan CH, Chang CC, Su CT, et al Trends in irritable bowel syndrome incidence among Taiwanese adults during 2003–2013: A population-based study of sex and age differences. PLoS One2016;11:e0166922.

    Not in our library10.1371/journal.pone.0166922

  36. 36.

    Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, et al Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis. Gut2008;57(11):1545–53.

    Not in our library10.1136/gut.2008.159723

  37. 37.

    Šimundić AM Measures of diagnostic accuracy: Basic definitions. ejifcc2009;19(4):203–11.

    Not in our library

  38. 38.

    Fuchs CS, Giovannucci EL, Colditz GA, et al a prospective study of family history and the risk of colorectal cancer. N Engl J Med1994;331(25):1669–74.

    Not in our library10.1056/nejm199412223312501

  39. 39.

    Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA2016;315(23):2564–75.

    Not in our library10.1001/jama.2016.5989

  40. 40.

    Bacchus CM, Dunfield L, Gorber SC, et al; Canadian Task Force on Preventive Health C, Recommendations on screening for colorectal cancer in primary care. CMAJ2016;188:340–8.

    Not in our library10.1503/cmaj.151125

  41. 41.

    Cash BD, Schoenfeld P, Chey WD The utility of diagnostic tests in irritable bowel syndrome patients: A systematic review. Am J Gastroenterol2002;97(11):2812–9.

    Not in our library10.1111/j.1572-0241.2002.07027.x

  42. 42.

    Canavan C, Card T, West J The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: A cohort study. PLoS One2014;9(9):e106478.

    Not in our library10.1371/journal.pone.0106478

  43. 43.

    Thomson AB, Barkun AN, Armstrong D, et al The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther2003;17(12):1481–91.

    Not in our library10.1046/j.1365-2036.2003.01646.x

  44. 44.

    Patel P, Bercik P, Morgan DG, et al Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: Cross-sectional survey. Scand J Gastroenterol2015;50(7):816–23.

    Not in our library10.3109/00365521.2015.1007079

  45. 45.

    Spiegel BM, Gralnek IM, Bolus R, et al Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?Gastrointest Endosc2005;62(6):892–9.

    Not in our library10.1016/j.gie.2005.08.016

  46. 46.

    Lin JS, Piper MA, Perdue LA, et al Screening for colorectal cancer: Updated evidence report and systematic review for the us preventive services task Force. JAMA2016;315(23):2576–94.

    Not in our library10.1001/jama.2021.4417

  47. 47.

    Brenner H, Stock C, Hoffmeister M Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: Systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ2014;348:g2467.

    Not in our library10.1136/bmj.g2467

  48. 48.

    Canavan C, West J, Card T The epidemiology of irritable bowel syndrome. Clin Epidemiol2014;6:71–80.

    Not in our library10.2147/clep.s40245

  49. 49.

    Atkinson W, Sheldon TA, Shaath N, et al Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. Gut2004;53(10):1459–64.

    Not in our library10.1136/gut.2003.037697

  50. 50.

    Park MI, Camilleri M Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil2006;18(8):595–607.

    Not in our library10.1111/j.1365-2982.2005.00745.x

  51. 51.

    Eswaran S, Tack J, Chey WD Food: The forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am2011;40(1):141–62.

    Not in our library10.1016/j.gtc.2010.12.012

  52. 52.

    Bischoff SC, Herrmann A, Manns MP Prevalence of adverse reactions to food in patients with gastrointestinal disease. Allergy1996;51(11):811–8.

    Not in our library

  53. 53.

    Dainese R, Galliani EA, De Lazzari F, et al Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients. Am J Gastroenterol1999;94(7):1892–7.

    Not in our library10.1111/j.1572-0241.1999.01226.x

  54. 54.

    Böhn L, Störsrud S, Törnblom H, et al Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol2013;108(5):634–41.

    Not in our library10.1038/ajg.2013.105

  55. 55.

    Capili B, Anastasi JK, Chang M Addressing the role of food in irritable bowel syndrome symptom management. J Nurse Pract2016;12(5):324–9.

    Not in our library10.1016/j.nurpra.2015.12.007

  56. 56.

    Simrén M, Månsson A, Langkilde AM, et al Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion2001;63(2):108–15.

    Not in our library10.1159/000051878

  57. 57.

    Tolliver BA, Jackson MS, Jackson KL, et al Does lactose maldigestion really play a role in the irritable bowel?J Clin Gastroenterol1996;23(1):15–7.

    Not in our library10.1097/00004836-199607000-00005

  58. 58.

    Vernia P, Ricciardi MR, Frandina C, et al Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactose-free diet. Ital J Gastroenterol1995;27(3):117–21.

    Not in our library

  59. 59.

    Parker TJ, Woolner JT, Prevost AT, et al Irritable bowel syndrome: Is the search for lactose intolerance justified?Eur J Gastroenterol Hepatol2001;13(3):219–25.

    Not in our library10.1097/00042737-200103000-00001

  60. 60.

    Bozzani A, Penagini R, Velio P, et al Lactose malabsorption and intolerance in Italians. Clinical implications. Dig Dis Sci1986;31(12):1313–6.

    Not in our library10.1007/bf01299809

  61. 61.

    Böhmer CJ, Tuynman HA The clinical relevance of lactose malabsorption in irritable bowel syndrome. Eur J Gastroenterol Hepatol1996;8(10):1013–6.

    Not in our library10.1097/00042737-199610000-00015

  62. 62.

    Böhmer CJ, Tuynman HA The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: A 5-year follow-up study. Eur J Gastroenterol Hepatol2001;13(8):941–4.

    Not in our library10.1097/00042737-200108000-00011

  63. 63.

    Ghoshal UC, Kumar S, Mehrotra M, et al Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea. J Neurogastroenterol Motil2010;16(1):40–6.

    Not in our library10.5056/jnm.2010.16.1.40

  64. 64.

    Sosa OR, Amieva-Balmori M, Galvez-Rios S, et al Glucose breath test in patients with overlapping FD and IBS. Is there any difference compared to patients with only FD or only IBS? [Abstract Tu1738]. Gastroenterology2016;150:S929–30.

    Not in our library

  65. 65.

    Ghoshal UC, Shukla R, Ghoshal U Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. Gut Liver2017;11(2):196–208.

    Not in our library10.5009/gnl16126

  66. 66.

    Pimentel M, Chow EJ, Lin HC Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol2000;95(12):3503–6.

    Not in our library10.1111/j.1572-0241.2000.03368.x

  67. 67.

    Dionne J, Ford AC, Yuan Y, et al A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol2018;113(9):1290–300.

    Not in our library10.1038/s41395-018-0195-4

  68. 68.

    Eswaran SL, Chey WD, Han-Markey T, et al A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol2016;111(12):1824–32.

    Not in our library10.1038/ajg.2016.434

  69. 69.

    Böhn L, Störsrud S, Liljebo T, et al Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology2015;149(6):1399–1407.e2.

    Not in our library10.1053/j.gastro.2015.07.054

  70. 70.

    McIntosh K, Reed DE, Schneider T, et al FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial. Gut2017;66(7):1241–51.

    Not in our library10.1136/gutjnl-2015-311339

  71. 71.

    Staudacher HM, Lomer MC, Anderson JL, et al Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr2012;142(8):1510–8.

    Not in our library10.3945/jn.112.159285

  72. 72.

    Staudacher H, Lomer M, Louis P, et al The low FODMAP diet reduces symptoms in irritable bowel syndrome compared with placebo diet and the microbiota alterations may be prevented by probiotic co-administration: a 2X2 factorial randomized controlled trial [Abstract 1133]. Gastroenterology2016;150:S230.

    Not in our library

  73. 73.

    Staudacher HM Nutritional, microbiological and psychosocial implications of the low FODMAP diet. J Gastroenterol Hepatol2017;32(Suppl 1):16–9.

    Not in our library10.1111/jgh.13688

  74. 74.

    Murray K, Wilkinson-Smith V, Hoad C, et al Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol2014;109(1):110–9.

    Not in our library10.1038/ajg.2013.386

  75. 75.

    Barrett JS, Gearry RB, Muir JG, et al Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther2010;31(8):874–82.

    Not in our library10.1111/j.1365-2036.2010.04237.x

  76. 76.

    Major G, Pritchard S, Murray K, et al Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome. Gastroenterology2017;152(1):124–33.e2.

    Not in our library10.1053/j.gastro.2016.09.062

  77. 77.

    Hayes P, Corish C, O’Mahony E, et al A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet2014;27(Suppl 2):36–47.

    Not in our library10.1111/jhn.12114

  78. 78.

    Halmos EP, Christophersen CT, Bird AR, et al Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut2015;64(1):93–100.

    Not in our library10.1136/gutjnl-2014-307264

  79. 79.

    Nanayakkara WS, Skidmore PM, O’Brien L, et al Efficacy of the low FODMAP diet for treating irritable bowel syndrome: The evidence to date. Clin Exp Gastroenterol2016;9:131–42.

    Not in our library10.2147/ceg.s86798

  80. 80.

    Biesiekierski JR, Newnham ED, Irving PM, et al Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial. Am J Gastroenterol2011;106:508–14; quiz 515.

    Not in our library10.1038/ajg.2010.487

  81. 81.

    Shahbazkhani B, Sadeghi A, Malekzadeh R, et al Non-celiac gluten sensitivity has narrowed the spectrum of irritable bowel syndrome: A double-blind randomized placebo-controlled trial. Nutrients2015;7(6):4542–54.

    Not in our library10.3390/nu7064542

  82. 82.

    Biesiekierski JR, Peters SL, Newnham ED, et al No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology2013;145:320–8 e1-3.

    Not in our library10.1053/j.gastro.2013.04.051

  83. 83.

    Gaesser GA, Angadi SS Gluten-free diet: Imprudent dietary advice for the general population?J Acad Nutr Diet2012;112(9):1330–3.

    Not in our library10.1016/j.jand.2012.06.009

  84. 84.

    Wild D, Robins GG, Burley VJ, et al Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. Aliment Pharmacol Ther2010;32(4):573–81.

    Not in our library10.1111/j.1365-2036.2010.04386.x

  85. 85.

    Lee AR, Ng DL, Zivin J, et al Economic burden of a gluten-free diet. J Hum Nutr Diet2007;20(5):423–30.

    Not in our library10.1111/j.1365-277x.2007.00763.x

  86. 86.

    Moayyedi P, Quigley EM, Lacy BE, et al The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol2014;109(9):1367–74.

    Not in our library10.1038/ajg.2014.195

  87. 87.

    Kamiya T, Shikano M, Tanaka M, et al Therapeutic effects of biobran, modified arabinoxylan rice bran, in improving symptoms of diarrhea predominant or mixed type irritable bowel syndrome: A pilot, randomized controlled study. Evid Based Complement Alternat Med2014;2014:828137.

    Not in our library10.1155/2014/828137

  88. 88.

    Singh B Psyllium as therapeutic and drug delivery agent. Int J Pharm2007;334(1-2):1–14.

    Not in our library10.1016/j.ijpharm.2007.01.028

  89. 89.

    Li CY, Ain Mohd Tahir N, Li SC A systematic review of integrated traditional Chinese and Western medicine for managing irritable bowel syndrome. Am J Chin Med2015;43(3):385–406.

    Not in our library10.1142/s0192415x15500251

  90. 90.

    Rahimi R, Abdollahi M Herbal medicines for the management of irritable bowel syndrome: A comprehensive review. World J Gastroenterol2012;18(7):589–600.

    Not in our library10.3748/wjg.v18.i7.589

  91. 91.

    Shi J, Tong Y, Shen JG, et al Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: A systematic review. World J Gastroenterol2008;14(3):454–62.

    Not in our library10.3748/wjg.14.454

  92. 92.

    Lim B, Manheimer E, Lao L, et al Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev2006;(4):CD005111.

    Not in our library10.1002/14651858.cd005111.pub2

  93. 93.

    Manheimer E, Cheng K, Wieland LS, et al Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev2012;(5):CD005111.

    Not in our library10.1002/14651858.cd005111.pub3

  94. 94.

    Lowe C, Aiken A, Day AG, et al Sham acupuncture is as efficacious as true acupuncture for the treatment of IBS: A randomized placebo controlled trial. Neurogastroenterol Motil2017;29(7):e13040.

    Not in our library10.1111/nmo.13040

  95. 95.

    White A, Hayhoe S, Hart A, et al Adverse events following acupuncture: Prospective survey of 32 000 consultations with doctors and physiotherapists. BMJ2001;323(7311):485–6.

    Not in our library10.1136/bmj.323.7311.485

  96. 96.

    Wu J, Hu Y, Zhu Y, et al Systematic review of adverse effects: A further step towards modernization of acupuncture in China. Evid Based Complement Alternat Med2015;2015:432467.

    Not in our library10.1155/2015/432467

  97. 97.

    Park SM, Kim WJ, Mun JH, et al Adverse events associated with acupuncture: A clinicopathologic review. Int J Dermatol2016;55(7):757–63.

    Not in our library10.1111/ijd.12914

  98. 98.

    Ford AC, Talley NJ, Spiegel BM, et al Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ2008;337:a2313.

    Not in our library10.1136/bmj.a2313

  99. 99.

    Merat S, Khalili S, Mostajabi P, et al The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci2010;55(5):1385–90.

    Not in our library10.1007/s10620-009-0854-9

  100. 100.

    Cash BD, Epstein MS, Shah SM A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci2016;61(2):560–71.

    Not in our library10.1007/s10620-015-3858-7

  101. 101.

    Mosaffa-Jahromi M, Lankarani KB, Pasalar M, et al Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome. J Ethnopharmacol2016;194:937–46.

    Not in our library10.1016/j.jep.2016.10.083

  102. 102.

    Khanna R, MacDonald JK, Levesque BG Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. J Clin Gastroenterol2014;48(6):505–12.

    Not in our library10.1097/mcg.0b013e3182a88357

  103. 103.

    Kabir MA, Ishaque SM, Ali MS, et al Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J2011;20(3):397–401.

    Not in our library

  104. 104.

    Ko SJ, Han G, Kim SK, et al Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med2013;2013:824605.

    Not in our library10.1155/2013/824605

  105. 105.

    Stevenson C, Blaauw R, Fredericks E, et al Randomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition2014;30(10):1151–7.

    Not in our library10.1016/j.nut.2014.02.010

  106. 106.

    Sisson G, Ayis S, Sherwood RA, et al Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–a 12 week double-blind study. Aliment Pharmacol Ther2014;40(1):51–62.

    Not in our library10.1111/apt.12787

  107. 107.

    Jafari E, Vahedi H, Merat S, et al Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med2014;17(7):466–70.

    Not in our library

  108. 108.

    Ludidi S, Jonkers DM, Koning CJ, et al Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil2014;26(5):705–14.

    Not in our library10.1111/nmo.12320

  109. 109.

    Yoon JS, Sohn W, Lee OY, et al Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol2014;29(1):52–9.

    Not in our library10.1111/jgh.12322

  110. 110.

    Abbas Z, Yakoob J, Jafri W, et al Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: A randomized trial. Eur J Gastroenterol Hepatol2014;26(6):630–9.

    Not in our library10.1097/meg.0000000000000094

  111. 111.

    Lorenzo-Zúñiga V, Llop E, Suárez C, et al I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol2014;20(26):8709–16.

    Not in our library10.3748/wjg.v20.i26.8709

  112. 112.

    Pineton de Chambrun G, Neut C, Chau A, et al A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis2015;47:119–24.

    Not in our library10.1016/j.dld.2014.11.007

  113. 113.

    Wong RK, Yang C, Song GH, et al Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: A randomized double-blinded placebo study. Dig Dis Sci2015;60(1):186–94.

    Not in our library10.1007/s10620-014-3299-8

  114. 114.

    Yoon H, Park YS, Lee DH, et al Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr2015;57(2):129–34.

    Not in our library10.3164/jcbn.15-14

  115. 115.

    Thijssen AY, Clemens CH, Vankerckhoven V, et al Efficacy of Lactobacillus casei Shirota for patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol2016;28(1):8–14.

    Not in our library10.1097/meg.0000000000000484

  116. 116.

    Spiller R, Pélerin F, Cayzeele Decherf A, et al Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: Improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol J2016;4(3):353–62.

    Not in our library10.1177/2050640615602571

  117. 117.

    Lyra A, Hillilä M, Huttunen T, et al Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol2016;22(48):10631–42.

    Not in our library10.3748/wjg.v22.i48.10631

  118. 118.

    Hod K, Sperber AD, Ron Y, et al A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Neurogastroenterol Motil2017;29(7):e13037.

    Not in our library10.1111/nmo.13037

  119. 119.

    Ford AC, Harris LA, Lacy BE, et al Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther2018;48(10):1044–60.

    Not in our library10.1111/apt.15001

  120. 120.

    Mercer M, Brinich MA, Geller G, et al How patients view probiotics: Findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol2012;46(2):138–44.

    Not in our library10.1097/mcg.0b013e318225f545

  121. 121.

    Ford AC, Quigley EM, Lacy BE, et al Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: Systematic review and meta-analysis. Am J Gastroenterol2014;109:1350–65; quiz 1366.

    Not in our library10.1038/ajg.2014.148

  122. 122.

    Fernandez C, Perez M, Amigo I, et al Stress and contingency management in the treatment of irritable bowel syndrome. Stress Med1998;14:31–42.

    Not in our library

  123. 123.

    Zernicke KA, Campbell TS, Blustein PK, et al Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: A randomized wait-list controlled trial. Int J Behav Med2013;20(3):385–96.

    Not in our library10.1007/s12529-012-9241-6

  124. 124.

    Boltin D, Sahar N, Gil E, et al Gut-directed guided affective imagery as an adjunct to dietary modification in irritable bowel syndrome. J Health Psychol2015;20(6):712–20.

    Not in our library10.1177/1359105315573450

  125. 125.

    Ford AC, Lacy BE, Harris LA, et al Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis. Am J Gastroenterol2018; doi:10.1038/s41395-018-0222-5.

    Not in our library10.1038/s41395-018-0222-5

  126. 126.

    Blanchard EB, Schwarz SP, Suls JM, et al Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther1992;30(2):175–89.

    Not in our library10.1016/0005-7967(92)90141-3

  127. 127.

    Payne A, Blanchard EB A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol1995;63(5):779–86.

    Not in our library10.1037//0022-006x.63.5.779

  128. 128.

    Guthrie E, Creed F, Dawson D, et al A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology1991;100(2):450–7.

    Not in our library10.1016/0016-5085(91)90215-7

  129. 129.

    Simrén M, Ringström G, Björnsson ES, et al Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. Psychosom Med2004;66(2):233–8.

    Not in our library10.1097/01.psy.0000116964.76529.6e

  130. 130.

    Laird KT, Tanner-Smith EE, Russell AC, et al Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. Clin Psychol Rev2017;51:142–52.

    Not in our library10.1016/j.cpr.2016.11.001

  131. 131.

    Clavé P, Acalovschi M, Triantafillidis JK, et al; OBIS Study Investigators Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther2011;34(4):432–42.

    Not in our library10.1111/j.1365-2036.2011.04730.x

  132. 132.

    Rai RR, Dwivedi M, Kumar N Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study. Saudi J Gastroenterol2014;20(6):378–82.

    Not in our library10.4103/1319-3767.145331

  133. 133.

    Zheng L, Lai Y, Lu W, et al Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, Controlled Trial. Clin Gastroenterol Hepatol2015;13(7):1285–1292.e1.

    Not in our library10.1016/j.cgh.2015.01.015

  134. 134.

    Chey WD, Kurlander J, Eswaran S Irritable bowel syndrome: A clinical review. JAMA2015;313(9):949–58.

    Not in our library10.1001/jama.2015.0954

  135. 135.

    Agger JL, Schröder A, Gormsen LK, et al Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): A double-blind, randomised study. Lancet Psychiatry2017;4(5):378–88.

    Not in our library10.1016/s2215-0366(17)30126-8

  136. 136.

    Verdu B, Decosterd I, Buclin T, et al Antidepressants for the treatment of chronic pain. Drugs2008;68(18):2611–32.

    Not in our library10.2165/0003495-200868180-00007

  137. 137.

    Grover M, Camilleri M Effects on gastrointestinal functions and symptoms of serotonergic psychoactive agents used in functional gastrointestinal diseases. J Gastroenterol2013;48(2):177–81.

    Not in our library10.1007/s00535-012-0726-5

  138. 138.

    Gorard DA, Libby GW, Farthing MJ Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther1994;8(2):159–66.

    Not in our library10.1111/j.1365-2036.1994.tb00273.x

  139. 139.

    Vahedi H, Merat S, Momtahen S, et al Clinical trial: The effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther2008;27(8):678–84.

    Not in our library10.1111/j.1365-2036.2008.03633.x

  140. 140.

    Vahedi H, Merat S, Rashidioon A, et al The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: A double-blind randomized-controlled study. Aliment Pharmacol Ther2005;22(5):381–5.

    Not in our library10.1111/j.1365-2036.2005.02566.x

  141. 141.
    Selective serotonin reuptake inhibitor (SSRI) antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved · 2013
    Not checked
  142. 142.

    Warner CH, Bobo W, Warner C, et al Antidepressant discontinuation syndrome. Am Fam Physician2006;74(3):449–56.

    Not in our library

  143. 143.

    Dekel R, Drossman DA, Sperber AD The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs2013;22(3):329–39.

    Not in our library10.1517/13543784.2013.761205

  144. 144.

    Hovdenak N Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl1987;130:81–4.

    Not in our library10.3109/00365528709091004

  145. 145.

    Lavö B, Stenstam M, Nielsen AL Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study. Scand J Gastroenterol Suppl1987;130:77–80.

    Not in our library10.3109/00365528709091003

  146. 146.

    Cann PA, Read NW, Holdsworth CD, et al Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci1984;29(3):239–47.

    Not in our library10.1007/bf01296258

  147. 147.

    Efskind PS, Bernklev T, Vatn MH A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol1996;31(5):463–8.

    Not in our library10.3109/00365529609006766

  148. 148.

    Baker DE Loperamide: A pharmacological review. Rev Gastroenterol Disord2007;7(Suppl 3):S11–8.

    Not in our library

  149. 149.

    Hanauer SB The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord2008;8(1):15–20.

    Not in our library

  150. 150.

    Wedlake L, A’Hern R, Russell D, et al Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther2009;30(7):707–17.

    Not in our library10.1111/j.1365-2036.2009.04081.x

  151. 151.

    Lombardo L, Schembri M A reason why lactose-free diet can be clinically ineffective in lactose intolerance patients [Abstract OP165]. United European Gastroenterol J2015;3:A54.

    Not in our library

  152. 152.

    Lembo A, Pimentel M, Rao SS, et al Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology2016;151(6):1113–21.

    Not in our library10.1053/j.gastro.2016.08.003

  153. 153.

    Sharara AI, Aoun E, Abdul-Baki H, et al A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol2006;101(2):326–33.

    Not in our library10.1111/j.1572-0241.2006.00458.x

  154. 154.

    Lembo A, Zakko S, Ferreira N, et al Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: SHORT term treatment leading to long term sustained response [Abstract T1390]. Gastroenterology2008;134:A545.

    Not in our library

  155. 155.

    Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med2011;364(1):22–32.

    Not in our library10.1056/nejmoa1004409

  156. 156.

    XIFAXAN® (Rifaximin) Prescribing Information, May 2015. Raleigh, NC: Salix Pharmaceuticals, Inc.

    Not in our library

  157. 157.

    Adachi JA, DuPont HL Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis2006;42(4):541–7.

    Not in our library10.1086/499950

  158. 158.

    Di Stefano M, Strocchi A, Malservisi S, et al Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther2000;14(8):1001–8.

    Not in our library10.1046/j.1365-2036.2000.00808.x

  159. 159.

    Dove LS, Lembo A, Randall CW, et al Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology2013;145(2):329–38.e1.

    Not in our library10.1053/j.gastro.2013.04.006

  160. 160.

    Lembo AJ, Lacy BE, Zuckerman MJ, et al Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med2016;374(3):242–53.

    Not in our library10.1056/nejmoa1505180

  161. 161.

    Smith L, Love B Eluxadoline in the treatment of irritable bowel syndrome with diarrhea. Clin Med Rev Ther2016;8:15–9.

    Not in our library

  162. 162.

    VIBERZITM (Eluxadoline) Product Monograph, Jan 2017. Markham, Ontario: Allergan Pharma Co.

    Not in our library

  163. 163.

    Longstreth GF, Yao JF Irritable bowel syndrome and surgery: A multivariable analysis. Gastroenterology2004;126(7):1665–73.

    Not in our library10.1053/j.gastro.2004.02.020

  164. 164.

    Hasler WL, Schoenfeld P Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther2003;17(8): 997–1005.

    Not in our library10.1046/j.1365-2036.2003.01499.x

  165. 165.

    Awad RA, Camacho S A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis2010;12(11):1131–8.

    Not in our library10.1111/j.1463-1318.2009.01990.x

  166. 166.

    Chapman RW, Stanghellini V, Geraint M, et al Randomized clinical trial: Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol2013;108(9):1508–15.

    Not in our library10.1038/ajg.2013.197

  167. 167.

    Ford AC, Brandt LJ, Young C, et al Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am J Gastroenterol2009;104(7):1831–43; quiz 1844.

    Not in our library10.1038/ajg.2009.223

  168. 168.

    Johanson JF, Drossman DA, Panas R, et al Clinical trial: Phase two study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther2008;27(8):685–96.

    Not in our library10.1111/j.1365-2036.2008.03629.x

  169. 169.

    Drossman DA, Chey WD, Johanson JF, et al Clinical trial: Lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther2009;29(3):329–41.

    Not in our library10.1111/j.1365-2036.2008.03881.x

  170. 170.

    Lacy BE, Levy LC Lubiprostone: A chloride channel activator. J Clin Gastroenterol2007;41(4):345–51.

    Not in our library10.1097/01.mcg.0000225665.68920.df

  171. 171.

    Ford AC, Lacy BE, Talley NJ Irritable Bowel Syndrome. N Engl J Med2017;376(26):2566–78.

    Not in our library10.1056/nejmra1607547

  172. 172.

    Yang Y, Fang J-Y, Xuo G, et al Efficacy and safety of linaclotide in patients with IBS-C: Results from a phase 3, randomized, double-blind, placebo-controlled trial in China and other regions [Abstract Mo1646]. Gastroenterology2016;150:S741.

    Not in our library

  173. 173.

    Johnston JM, Kurtz CB, Macdougall JE, et al Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology2010;139(6):1877–1886.e2.

    Not in our library10.1053/j.gastro.2010.08.041

  174. 174.

    Chey WD, Lembo AJ, Lavins BJ, et al Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol2012;107(11):1702–12.

    Not in our library10.1038/ajg.2012.254

  175. 175.

    Rao S, Lembo AJ, Shiff SJ, et al A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol2012;107(11):1714–24; quiz p.1725.

    Not in our library10.1038/ajg.2012.255

  176. 176.

    McCormack PL Linaclotide: A review of its use in the treatment of irritable bowel syndrome with constipation. Drugs2014;74(1):53–60.

    Not in our library10.1007/s40265-013-0157-5

  177. 177.

    CONSTELLATM (Linaclotide) Product Monograph, May 2014. Vaughan, Ontario: Forest Laboratories Canada, Inc.

    Not in our library

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.